- Home
- FRHC vs EXEL Comparison
FRHC vs EXEL Comparison
Compare FRHC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRHC
- EXEL
- Stock Information
- Founded
- FRHC 1981
- EXEL 1994
- Country
- FRHC United States
- EXEL United States
- Employees
- FRHC N/A
- EXEL 1147
- Industry
- FRHC Investment Bankers/Brokers/Service
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRHC Finance
- EXEL Health Care
- Exchange
- FRHC Nasdaq
- EXEL Nasdaq
- Market Cap
- FRHC 9.5B
- EXEL 11.3B
- IPO Year
- FRHC N/A
- EXEL 2000
- Fundamental
- Price
- FRHC $138.29
- EXEL $40.37
- Analyst Decision
- FRHC
- EXEL Buy
- Analyst Count
- FRHC 0
- EXEL 18
- Target Price
- FRHC N/A
- EXEL $39.59
- AVG Volume (30 Days)
- FRHC 151.1K
- EXEL 2.6M
- Earning Date
- FRHC 08-08-2025
- EXEL 08-05-2025
- Dividend Yield
- FRHC N/A
- EXEL N/A
- EPS Growth
- FRHC N/A
- EXEL 237.58
- EPS
- FRHC 1.40
- EXEL 2.20
- Revenue
- FRHC $1,462,948,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- FRHC N/A
- EXEL $9.37
- Revenue Next Year
- FRHC N/A
- EXEL $11.05
- P/E Ratio
- FRHC $100.31
- EXEL $18.12
- Revenue Growth
- FRHC 33.85
- EXEL 24.49
- 52 Week Low
- FRHC $71.88
- EXEL $21.36
- 52 Week High
- FRHC $185.00
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- FRHC 37.42
- EXEL 42.39
- Support Level
- FRHC $145.94
- EXEL $41.03
- Resistance Level
- FRHC $158.47
- EXEL $42.07
- Average True Range (ATR)
- FRHC 6.79
- EXEL 0.95
- MACD
- FRHC -2.44
- EXEL -0.42
- Stochastic Oscillator
- FRHC 4.78
- EXEL 12.85
About FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.